Accessibility statement

Mark Sculpher



Mark Sculpher is Professor of Health Economics and is Team Leader of the Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU). He has been based at York University since 1997. 

Between 1988 and 1997, he worked at the Health Economics Research Group at Brunel University; during 1998 he was a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada.

Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 250 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the economic evaluation of health care programmes (OUP, 2015 with Drummond, Claxton, Torrance, and Stoddart) and Decision modelling for health economic evaluation (OUP, 2006 with Briggs and Claxton). He was a member of the Second Panel on Cost-Effectiveness in Health and Medicine.

Mark was a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee between 2004 and 2008, the NICE Public Health Interventions Advisory Committee between 2006 and 2009 and currently sits on the NICE Diagnostics Advisory Committee. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance. He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme between 2007 and 2010, and the UK National Institute for Health Research (NIHR)/Medical Research Council (MRC) Methodology Research Panel between 2008 and 2011. He was a member of the NIHR Policy Research Programme’s Commissioning Panel from 2011-2014. He is currently a member of the MRC-NIHR Methodology Research Advisory Group. Mark is a NIHR Senior Investigator (Emeritus) and is a former President of the International Society of Pharmacoeconomics and Outcomes Research.



  • Decision analytic modelling, analysis of uncertainty and heterogeneity, pharmaceutical policy, economic evaluation and decision making

Research group(s)


  • National Institute for Health Research HTA Programme
    • Programme of Technology Assessment Reviews for the National Institute for Health and Care Excellence
    • Economic Evaluation of Health and Care Interventions Policy Research Unit (EEPRU)
    • Long-term cost-effectiveness of endovascular aneurism repair
    • Evaluation of multi-functional magnetic resonance imaging in the diagnosis and characterisation of prostate cancer
    • Economic evaluation of screening and diagnostic tests to identify and treat women with gestational diabetes
    • Cost-effectiveness of alternative approaches to identifying and managing individuals with familial hypercholesterolaemia
  • National Institute for Health Research (NIHR)
    • Improving the quality of care of patients with angina and heart attack
    • Acupuncture for chronic pain and depression in primary care
    • Research Design Service – support in developing research by local clinicians and other researchers
  • Global Health
    • HIV modelling consortium (Bill and Melinda Gates Foundation)
    • Optimising Clinical Care in HIV (DFID)
    • Thanzi la Onse (Health of All): Frameworks and analysis to ensure value for money health care - developing theory,changing practice (GCRF, RCUK)
  • NIHR/Medical Research Council Methodology Research Programme
    • Methods for estimation of the NICE cost-effectiveness threshold
  • British Heart Foundation 
    • Cost-effectiveness of magnetic resonance imaging in coronary heart disease (CEMARC-2)


Mark Sculpher is part of the Thesis Advisory Group for:

External activities


Editorial duties

Recent Presentations

  • Invited short course on decision analysis. The Prince Mahidol Conference, Bangkok 26-21 January 2016.
  • Keynote talk entitled ‘Making Economic Evaluation Fit for Purpose to Support Decisions’. The Third Annual Global Health Economics Consortium Colloquium:Valuing Health. University of California San Francisco, 12th February 2016.
  • Invited ‘rounds’ at the University of Toronto, talk entitled ‘CEA Should be the Primary Decision Making Criterion in Decisions about Health Technology and Services’. Toronto, 20th May 2016.
  • Invited talk at Centre for Global Development, entitled ‘Enduring Challenges in Specifying Economic Analysis to Support Resource Allocation Decisions:Reflections on Two Guidelines’. Washington DC, 23rd May 2016.
  • Talk entitled ‘Cost-effectiveness Thresholds: Should we be Generating More Empirical Evidence and, if so, How?’. Issues Panel at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Washington DC, 24th May 2016. Sculpher ISPOR May 2016 (PDF , 161kb)
Staff Photo for Mark Sculpher

Contact details

Mark Sculpher
Centre for Health Economics